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Background: Sero-positivity rates of the rubella virus among pregnant women vary widely throughout the world.
In Tanzania, rubella vaccination is not included in the national immunization schedule and there is therefore no
antenatal screening for this viral disease. So far, there are no reports on the sero-prevalence of rubella among
pregnant women in Tanzania. As a result, this study was undertaken to establish the sero-positivity rate of rubella
and rubella risk factors among pregnant women attending antenatal care clinics in Mwanza, Tanzania.
Methods: From November 2012 to May 2013 a total of 350 pregnant women were enrolled and their serum
samples collected and analyzed using the AXSYM anti-rubella virus IgG/IgM-MEIA test. Demographic and clinical
data were collected using a standardized data collection tool. Data analysis was done using STATA version 12.
Results: Of 342 pregnant women tested for rubella antibodies, 317 (92.6%) were positive for anti-rubella IgG while only
1 (0.3%) was positive for IgM. Higher sero-positivity rates were found in the age group of 25–44 years. Furthermore, it
was observed that with each year increase in age, the risk of contracting rubella increases by 12% (OR = 1.12, 95% CI:
1.02-1.22, P = 0.019). Women involved in farming and business women were at a higher risk of contracting rubella infection
compared to formally employed women (OR: 4.9, P = 0.011; OR 7.1, p = 0.003 respectively). In univariate analysis, the risk
of contracting rubella virus infection was found to increase with gestational age with a statistical significance.
Conclusions: Sero-positivity rates of rubella are high in Mwanza and are significantly associated with an increase in
age and being a farmer or a business woman. Screening of rubella and immunization of women at risk are highly
recommended in this area with a high non-immune rate against rubella virus.
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Rubella is habitually a self-limiting disease. However, if
contracted during pregnancy, it may result in miscarriage,
stillbirth or an infant born with congenital rubella syn-
drome (CRS), characterized by deafness, heart disease, cat-
aracts or other permanent congenital manifestations [1,2].
In developing countries, more than 100,000 children are
born with CRS each year [2,3]. The sero-positivity for ru-
bella among pregnant women varies widely in different* Correspondence: mshana72@yahoo.com
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reproduction in any medium, provided the orcountries. As a matter of fact, in many developing coun-
tries, rubella sero-positivity among pregnant women has
been reported to range from 54.1% to 95.2% [1,2,4,5].
Clinical diagnosis of rubella during pregnancy proves diffi-
cult as only approximately 50% of the infected people
present with typical exanthematous skin lesions [1,6].
Hence, serological screening of rubella, based on the de-
tection of IgG and IgM antibodies, remains the mainstay
for diagnosis [3]. Since no specific treatment exists for ru-
bella, vaccination before pregnancy is the only mean to
prevent congenital infection. In developed countries, rubella
infections are indeed prevented by active immunization
given as part of a MMR vaccine [6]. WHO recommends
that susceptible pregnant women be vaccinated as soon asral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Distribution of rubella sero-prevalence along with
demographic characteristics among pregnant women,
Mwanza, 2013
Rubella sero-status (N = 342) Total
Characteristic Sero-positivity Sero-negativity
n % n %
Age (Yr)
15-24 152 89.4 18 10.6 170
25-34 142 95.9 6 4.1 148
35-44 23 95.8 1 4.2 24
Residence
Urban 146 90.6 15 9.4 161
Rural 171 94.5 10 5.0 181
Occupation
Business 90 93.8 6 6.3 96
Farmer 202 94.4 12 5.6 214
Employed 25 78.1 7 21.9 32
Education
Illiterate 18 85.7 3 14.3 21
Primary 219 92.4 18 7.6 237
Secondary+ 80 95.2 4 4.8 84
Marital status
Married 269 93.1 20 6.6 289
Unmarried 48 90.6 5 9.4 53
Trimester
1st Trimester 13 81.2 3 18.8 16
2nd Trimester 171 90.9 17 9.1 188
3rd Trimester 133 96.3 5 3.7 138
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Tanzania, rubella vaccination is not included in the na-
tional immunization programme [2].
In Tanzania and other neighbouring countries, there
are no screening programs for rubella among pregnant
women and the magnitude of the problem is therefore
unknown. This study was carried out to determine the
sero-positivity rates and the predictors of rubella infec-
tion among pregnant women attending antenatal clinics
in Mwanza, Tanzania.
Methods
This was a cross-sectional study conducted between
November 2012 and May 2013 in Mwanza city, Tanzania.
The study involved three antenatal care clinics: UMATI
and Sekou-Toure Regional Hospital, located in an urban
area, and Igombe Health Centre, located in a rural setting.
The sample size of 322 was calculated using a formula
suitable for cross-sectional studies [7,8]. The study en-
rolled 350 pregnant women from the 3 clinics individual
sample size for each clinic was a proportion of the total
sample size calculated on the basis of the number of preg-
nant women, attending those clinics.
Data collection and laboratory procedures
Data were collected using a standardized data collection
tool. Information on socio-demographic characteristics
and relevant medical and obstetric characteristics were
gathered. About 4 ml of venous blood was taken from
each participant. A total of 350 samples were collected:
n = 180, in Igombe (rural area) and n = 170 in UMATI
and Sekou-Toure (urban area). All samples were trans-
ported to the Bugando Medical Centre, where the serum
was separated from the whole blood. The obtained
serum samples were numbered and kept at −80°C until
transportation to Germany for subsequent analysis of
rubella-specific IgG and IgM antibodies using AxSYM
rubella virus IgG/IgM-MEIA (Abbott, IL, USA). Manufac-
turer reference values for positive results were anti-rubella
IgG ≥ 10 IU/ml and anti-rubella IgG < 10 IU/ml for nega-
tive results while anti-rubella IgM > 0.8 was considered as
positive and anti-rubella IgM < 0.6 as negative. An IgM
value between 0.6-0.8 was considered as borderline.
Data analysis
The programme Microsoft Office Excel 2007 was used
to enter the data according to codes given and data were
analyzed using the STATA version 12 (College Station,
Texas, USA). Categorical variables were summarized as
proportions and were analyzed using the Pearson’s Chi-
square test to observe the differences among the various
groups. Continuous variables were summarized as me-
dian with interquartile range. Univariate analysis and
multivariate logistic regression models were fitted todetermine the predictors of rubella infection. Predictors
with p-value less than 0.2 were fitted into the multivariate
logistic regression analysis and their odds ratios and 95%
confidence interval were noted. Predictors with p-value of
less than 0.05 were considered statistically significant.Ethical approval
The study protocol was approved by the CUHAS/BMC
Ethics Review Board. An informed written consent was
sought from each pregnant woman prior to her enrolment.Results
Out of the 350 enrolled women, 342 had a valid analysis for
rubella infection and were included in the final analysis.
The median maternal age of the participants was 25 years.
A total of 181 (52.9%) pregnant women were from rural
areas and 32 (9.3%) of all pregnant women were employed.
Fifty-five (55%) and 40% of the women were in their second
and third trimester of pregnancy respectively. Eighty-five
percent (85%) of the women were married (Table 1).
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tested positive for anti-rubella IgG while only 1 (0.3%)
was positive for IgM, indicating an acute infection with
the rubella virus. A total of 25 women (7.3%) had a IgG
titre of less than 10 IU, thus being at risk of contracting
rubella infection during pregnancy. The sero-positivity
rate was slightly higher among pregnant women residing
in rural than in urban areas (94.5% vs. 90.6%) but this
difference was not statistically significant (OR 1.7, 95%
(0.77-4.03, p = 0.183). A higher prevalence of rubella-
specific IgG antibodies was observed in the age group
25–34 than in the age group 15–24. It was observed that
as the age increases by one year the risk of contracting
rubella increases by 12% (OR = 1.12, 95% CI 1.02-1.22,
p = 0.019) (Table 2, Figure 1). Farmers and business
women had significantly higher sero-positivity rates than
employed women (OR 4.9, p = 0.011; OR 7.1, p = 0.003 re-
spectively) {Table 2}. No statistical difference was observed
between sero-positivity and gravidity (OR 0.9, 95% CI
0.6-1.4, p = 0.561) while the risk of contracting rubella was
higher in the third trimester than in the first and second
trimesters (OR 6.1, 95% CI 1.3-28.6, p = 0.021). Similar
findings were obtained when gestational age (GA) was an-
alyzed as a continuous variable: the median GA was
higher for positive women than for negative women (26
vs. 21; OR 1.1, 95% CI 0.99-1.1.12, p = 0.055).
Discussion
To the best of our knowledge, this is the first study in
Tanzania to provide rubella sero-prevalence data among
pregnant women attending prenatal care clinics. InTable 2 Risk factors associated with Rubella infection among
Character Sero-status
Positive Negative OR
n (%) n (%)
*ƗAge 25 [22–29] 23 [19–25] 1.1 (
ƗResidence
Urban 146 (90.7) 15 (9.3)
Rural 171 (94.5) 10 (5.5) 1.7 (
ƗOccupation
Employed 25 (78.1) 7 (21.9)
Farmers 202 (94.4) 12 (5.6) 4.7
Business 90 (93.8) 6 (6.3) 4.2
*ƗGravidity 2 [1-4] 2 [1,2] 1.4 (
Trimester
1st 13 (81.2) 3 (18.8)
2nd 171 (91.0) 17 (9.0) 2.3
3rd 133 (96.4) 5 (3.60) 6.1
*Gestational age 26 [20–32] 21 [18–26] 1.1 (1
*Median; ƗFactors adjusted for.Tanzania and neighbouring countries (Kenya, Uganda,
Burundi, Democratic Republic of Congo) there are no
rubella immunization programmes, and routine rubella
screening during pregnancy is not practiced. The sero-
prevalence of 92.6% in Mwanza is very high, suggesting
a continuous transmission of endemic rubella virus in
the region. The reported sero-prevalence in this study is
higher than 85.8%, 77%, and 53% reported from Southern
Italy [9], Ouagadougou-Burkina Faso [8], Benin-Niger
[10], Sudan [11], Taiwan [12] and Nigeria [13]. When cate-
gorized by age, the sero-positivity rate of 89% for the age
group 15–25 years is lower than 94% observed in Kenya
[14] for age group 14-20 years. No study was found in
Uganda investigating the sero-positivity of rubella among
pregnant women but the sero-positivity in our study is
lower than the one reported among health workers in
Uganda [15] whereby 98% of them were rubella sero-
positive. These data suggest that there is a high transmis-
sion rate of the rubella virus in East Africa. As in previous
African studies [16,17], a low rate of acute infections was
found in the current study. However, this might not
reflect the true picture as women were not screened
during early pregnancy and followed-up. The sero-
prevalence in various trimesters is still higher than that
from other African countries with no immunization
programme [11,13,14,18,19].
The current study indicates that a considerable num-
ber of pregnant women in Mwanza are at risk of acquir-
ing primary infection with the rubella virus. There is no
vaccination against rubella, either in the public or pri-
vate sector in Mwanza, or anywhere in Tanzania. Inpregnant women (N = 342) in Mwanza, 2013
Crude Adjusted
(95% CI) p-value OR (95% CI) p-value
1.02-1.22) 0.019 1.2 (1.02-1.33) 0.021
1
0.77-4.01) 0.183 2.1 (0.7-6.7) 0.191
1 1
(1.7-13.1) 0.003 4.9 (1.4-16.6) 0.011
(1.3-13.6) 0.017 7.1 (1.9-26.3) 0.003
0.99-1.86) 0.057 0.9 (0.6-1.4) 0.561
1
(0.6-8.9) 0.222 - -
(1.3-28.6) 0.021
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Figure 1 Age specific Sero-prevalence of rubella infections. There is an increase of sero-prevalence of rubella infection with an increase in
age. The sero-prevalence increases by 1.6% with one year increase in age. The risk (odds ratios) of acquiring rubella infection increases by 12%
with one year increase in age.
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at an age between 15–24 are at risk of contracting the
rubella virus therefore being at an increased risk of CRS
[1,17,18]. Overall, 7.3% of the women of Mwanza are at
risk of acquiring primary rubella infection during preg-
nancy. This is higher than the figure of 7% observed in
Eldoret Kenya [19] and necessitates the introduction of
prenatal screening and routine immunization of all
women at risk. Both Kenya and Tanzania do not have
rubella immunization programme therefore the high
sero-positivity rates found in Eastern African countries
might be due to high transmission rates of infection.
Since there is no treatment for an active infection during
pregnancy, screening and immunization of women at
risk is the mainstay of preventing CRS [2]. Policy makers
should therefore consider implementing the above men-
tioned strategies.
In the present study, as in a South African one [18], it
was noted that women involved in business and farming
activities are a higher risk of acquiring rubella infection
compared to formally employed women. A high social
economic status, which implies good living conditions,
has been found to be associated with a lower risk to ac-
quire rubella infection [20]. As in studies undertaken in
Kenya [14,19], an increase in age was associated with an
increase in rubella sero-positivity. A large proportion of
women in Tanzania are involved in farming activities
and reside in villages, and they also tend to have their
first pregnancy at a low age (15–24). All these factors, as
evidenced by this study, put them at risk of acquiring ru-
bella infection and consequently increase the risk of de-
veloping CRS. In the current study, the third trimesterwas a risk of IgG sero-positivity, as demonstrated by uni-
variate analysis. It was also noted that as GA increases
the IgG sero-positivity increases. This indicates that
women of this geographical area may be contracting
acute rubella infection in early pregnancy. Further inves-
tigations are required to follow up these women for pos-
sible CRS.
Due to the cross-sectional nature of the study design,
follow-up of the participants was not undertaken. This is
an important limitation. However, the study established
the magnitude and some of the factors associated with ru-
bella sero-prevalence and recommended future studies.
Conclusion
Sero-positivity of rubella is high in the Mwanza region
with a significant proportion of women at risk of con-
tracting primary rubella infection. Advanced age and be-
ing a woman involved in farming or a business woman
were independent risk factors associated with positive
rubella infection. Screening for rubella infection during
antenatal care and post-natal immunization of women at
risk should be considered in Tanzania, as a major strat-
egy to minimize CRS. Susceptible pregnant women
should be thoroughly evaluated for possible rubella in-
fection. Women who were immune in their first preg-
nancy should not be vaccinated, as they have naturally
acquired immunity. In addition to the above interven-
tions, defining the target population age for rubella vac-
cination is a key issue. An efficient programme for
selective immunization of pre-pubertal/adolescent girls
should be considered, possibly as a critical component
of the school health system. A future study including
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identification of the most susceptible time frame of in-
fection in Tanzania. We also strongly recommend a large
follow up study of pregnant women to determine the
outcome of the pregnancy and the magnitude of CRS in
our settings.
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